Skip to main content

Table 1 Baseline clinical trial characteristics

From: Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology

  Variables Number of trials (%)
Phase II 10 (14)
III 57 (80)
Unspecified 4 (6)
Type of Tumor Breast 13 (18)
Genitourinary 10 (14)
Gastrointestinal 6 (8)
Lung 10 (14)
Other solid tumors 14 (20)
Hematological 12 (17)
Any cancer 6 (8)
Publication JCO 52 (73)
NEJM 17 (24)
Lancet 2 (3)
Registry Clinicaltrials.gov 62 (87)
ISRCT 5 (7)
EudraCT 2 (3)
ANZCTR 1 (1)
NTR 1 (1)
Type of Intervention Chemotherapy 22 (31)
Targeted therapy 26 (37)
Chemotherapy and radiation 6 (8)
Surgery or radiation 6 (8)
Supportive care 11 (15)
Trial Initiation Period 1994–2005 30 (42)
2006–2010 41 (58)
Trial Result Negative 37 (52)
Positive 34 (48)
Funding Source Non-pharma 33 (46)
Pharma 38 (54)
Length of Trial <  3 years 30 (42)
≥  3 years 41 (58)
Protocols with endpoints Primary endpoints 71 (100)
Secondary endpoints 71 (100)
Exploratory endpoints 28 (39)
  1. Abbreviations: JCO Journal of Clinical Oncology, NEJM New England Journal of Medicine, ISRCT International Standard Randomized Control Trial, EudraCT European Clinical Trials Database, ANZCTR Australian New Zealand Clinical Trial Registry, NTR Netherlands National Trial Register